The litigation, Holtzman v. Beta Bionics, Inc. et al., claims the company misled shareholders regarding its iLet Bionic Pancreas insulin pump. According to the complaint, the device utilized an aggressive dosing algorithm that allegedly caused hundreds of life-threatening hypoglycemic events requiring emergency medical intervention. The lawsuit further asserts that Beta Bionics suppressed thousands of customer complaints and failed to report these issues to the U.S. Food and Drug Administration.
Investors Face November Deadline in Beta Bionics Securities Lawsuit
Investors who purchased Beta Bionics common stock between July 30, 2025, and February 24, 2026, have until November 3, 2026, to file as lead plaintiffs in a class action lawsuit. The case, pending in the Central District of California, centers on allegations of undisclosed device malfunctions and regulatory failures.
Legal counsel from Kahn Swick & Foti, LLC, representing the plaintiffs, notes that the company’s internal challenges were deeper than previously disclosed. While the firm initially characterized an FDA Form 483 as a minor interpretative disagreement, the lawsuit alleges the document actually identified over 18,000 unreported complaints. Furthermore, the company reportedly failed to implement corrective measures following an FDA warning letter concerning its quality management and reporting systems. Investors seeking to participate in the recovery process should contact managing partner Lewis Kahn before the November 3 cutoff.
Comments (0)
No comments yet. Be the first!